Table 2.
Relationship between treatment response and clinical and demographic variables
| Characteristic | SVR, n = 34 (41.5 %) | R/NR, n = 48 (58.5 %) | p-Value |
|---|---|---|---|
| Age at the end of treatment (years) | |||
| Median (range) | 15.5 (4–17) | 14 (5–17) | 0.420 |
| <12 | 5 (14.7 %) | 9 (18.8 %) | 0.632 |
| Gender | |||
| Girls | 15 (44.1 %) | 19 (39.6 %) | 0.681 |
| Boys | 19 (55.9 %) | 29 (60.4 %) | |
| Liver fibrosis (F) stage (Scheuer) | |||
| Available | 32 | 46 | |
| F0–F1 | 17 (53.1 %) | 28 (60.9 %) | 0.529 |
| F2–F4 | 15 (46.9 %) | 18 (39.1 %) | |
| Liver activity (A) grade (Scheuer) | |||
| Available | 32 | 46 | |
| A0–A1 | 16 (50.0 %) | 19 (41.3 %) | 0.626 |
| A2–A4 | 16 (50.0 %) | 27 (58.7 %) | |
| Baseline ALT (U/l) | |||
| Median (range) | 33.5 (10–191) | 42.5 (19–285) | 0.087 |
| Abnormal | 18 (52.9 %) | 30 (62.5 %) | |
| Baseline GGTP (U/l) | |||
| Median (range) | 22 (6–94) | 27.5 (6–122) | 0.158 |
| Abnormal | 4 (11.8 %) | 10 (20.8 %) | |
| HCV genotype | |||
| 1 | 22 (64.7 %) | 27 (56.3 %) | 0.442 |
| 4 | 12 (35.3 %) | 21 (43.7 %) | |
| Baseline viral load (IU/ml) | |||
| Median (range), ×105 | 4.3 (0.037–30.2) | 3.5 (0.25–54.5) | 0.290 |
| ≥600,000 | 14 (41.2 %) | 18 (37.5 %) | 0.737 |
| ≥800,000 | 5 (14.7 %) | 14 (29.2 %) | 0.126 |
| After 12 weeks of treatment | |||
| EVR | 34 (100.0 %) | 22 (45.8 %) | –a |
| cEVR | 20 (58.8 %) | 5 (10.4 %) | –a |
aNot tested due to discontinuation of treatment in patients who did not achieve EVR